Tudor Investment Corp ET AL Increases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Tudor Investment Corp ET AL increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 59.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,618 shares of the biopharmaceutical company’s stock after purchasing an additional 9,180 shares during the period. Tudor Investment Corp ET AL’s holdings in Vanda Pharmaceuticals were worth $118,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in VNDA. Barclays PLC boosted its position in shares of Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 86,677 shares during the period. Norges Bank purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at $551,000. JPMorgan Chase & Co. grew its position in Vanda Pharmaceuticals by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock valued at $754,000 after acquiring an additional 22,249 shares during the last quarter. SG Americas Securities LLC grew its position in Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 5,459 shares during the last quarter. Finally, Monaco Asset Management SAM increased its stake in Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after purchasing an additional 188,836 shares during the period. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VNDA. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Insiders Place Their Bets

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the acquisition, the chief executive officer now owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. This represents a 0.44 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased a total of 32,000 shares of company stock worth $151,180 over the last 90 days. Company insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Trading Down 6.2 %

Shares of Vanda Pharmaceuticals stock opened at $3.96 on Friday. The stock’s fifty day moving average price is $4.52 and its 200-day moving average price is $4.65. The firm has a market cap of $233.38 million, a P/E ratio of -12.38 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 12 month low of $3.85 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. Analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.